

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

POSITIVE PROFIT ALERT

This announcement is published by the Company simultaneously on the Shanghai Stock Exchange pursuant to the Rules Governing the Listing of Stocks on Shanghai Stock Exchange and on The Stock Exchange of Hong Kong Limited pursuant to the disclosure obligations under Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The Board hereby announces that the Company is expecting to record an increase in the net profit attributable to shareholders of the Company for the six months ended June 30, 2021 in comparison with the corresponding period of 2020.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

This announcement is published by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) simultaneously on the Shanghai Stock Exchange pursuant to the Rules Governing the Listing of Stocks on Shanghai Stock Exchange and on The Stock Exchange of Hong Kong Limited pursuant to the disclosure obligations under Rule 13.09(2) (a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The board of directors of the Company (the “**Board**”) hereby announces that the Company (together with its subsidiaries, the “**Group**”) is expecting to record an increase in the net profit attributable to shareholders of the Company for the six months ended June 30, 2021 in comparison with the corresponding period of 2020.

Details of and the reasons for such estimated increase are set out below.

Important Notice:

1. The net profit attributable to shareholders of the Company was estimated to increase by a range between RMB910.0924 million to RMB944.4355 million for the first half of 2021, as compared with RMB1,717.1554 million for the first half of 2020, representing a year-over-year increase of a range between 53% to 55%.
2. The net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss was estimated to increase by a range between RMB972.7540 million to RMB995.3762 million for the first half of 2021, as compared with RMB1,131.1093 million for the first half of 2020, representing a year-over-year increase of a range between 86% to 88%.

I. ESTIMATED RESULTS FOR THE CURRENT PERIOD

(1) Period to which the estimated results apply

January 1, 2021 to June 30, 2021.

(2) Estimated Results

1. Based on the preliminary calculation by the finance department of the Company, net profit attributable to shareholders of the Company was estimated to increase by a range between RMB910.0924 million to RMB944.4355 million for the first half of 2021, as compared with RMB1,717.1554 million for the first half of 2020, representing a year-over-year increase of a range between 53% to 55%.
2. The net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss was estimated to increase by a range between RMB972.7540 million to RMB995.3762 million for the first half of 2021, as compared with RMB1,131.1093 million for the first half of 2020, representing a year-over-year increase of a range between 86% to 88%.

(3) The estimated operating results have not been audited by a certified public accountant.

II. RESULTS OF THE CORRESPONDING PERIOD LAST YEAR

- (1) Net profit attributable to the shareholders of the Company: RMB1,717.1554 million. Net profit attributable to the shareholders of the Company after deducting the non-recurring profit or loss: RMB1,131.1093 million.
- (2) Earnings per share (basic): RMB0.75 (The Company implemented the 2020 profit distribution and capital reserve conversion plan in year 2021, with 2 new shares issued for every 10 existing shares. According to the number of shares after the conversion, the basic earnings per share for the six months ended June 30, 2020 is adjusted to RMB0.63.)

III. MAIN REASONS FOR THE ESTIMATED GROWTH IN RESULTS FOR THE CURRENT PERIOD

(1) Impact of the principal business

The Company estimated that the growth rates of net profit attributable to the shareholders of the Company and net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss shall both exceed 50% driven by the following two factors:

1. From revenue perspective, capitalizing on the strong growth momentum in the first quarter of 2021, and with promising development of Contract Development and Manufacturing Organization (CDMO) and other businesses, the Company continued to record significant increase in revenue in the second quarter of 2021. The impact on cost due to the COVID-19 pandemic in China during the comparable period has been basically eliminated, and therefore Clinical Research and other Contract Research Organization (CRO) services achieved high growth compared to the same period of last year.
2. From operating profit perspective, the Company has fully recovered from low productivity period during the COVID-19 pandemic in the same period of last year. Productivity and operating efficiency continued to improve leading to significant growth in operating profit.

(2) Impact of non-recurring profit or loss

In the first half of 2021, the impact of the non-recurring profit or loss increased as compared with the corresponding period last year, mainly attributable to the relatively greater growth in gains from fair value change of certain non-current financial assets and investment gains of the Company due to increase in market values of listed and unlisted portfolios held by the Company. This was estimated to result in approximately RMB2,048.7629 million in profit for the first half of 2021, while the impact of the corresponding period last year was a net profit of RMB1,031.1589 million. In addition, fair value of the derivative instrument portion of the H-share convertible bonds of the Company was affected by the significant increase in stock price of the H-shares of the Company. The non-cash fair value loss on book was estimated to be approximately RMB1,493.3398 million for the first half of 2021, while the impact of the corresponding period last year was a net loss of RMB486.7990 million.

IV. RISK WARNING

There are no significant uncertainties pertaining to the Company identified as at the date of this announcement which may affect the accuracy of the estimated results.

V. OTHER INFORMATION

The Board would like to remind the investors that the above estimated results of the Company for the six months ended June 30, 2021 were prepared based on preliminary accounting information only. Please refer to the announcement of the unaudited 2021 interim results of the Company to be published subsequently for the finalized financial figures. Investors are advised to pay attention to the investment risks.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.
Dr. Ge Li
Chairman

Hong Kong, July 15, 2021

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purpose only*